O	0	10	Randomized
O	11	16	phase
O	17	19	II
O	19	20	,
O	21	27	double
O	27	28	-
O	28	33	blind
O	33	34	,
O	35	42	placebo
O	42	43	-
O	43	53	controlled
O	54	59	study
O	60	62	of
B-intervention	63	73	exemestane
I-intervention	74	78	with
I-intervention	79	81	or
I-intervention	82	89	without
I-intervention	90	100	entinostat
O	101	103	in
O	104	118	postmenopausal
O	119	124	women
O	125	129	with
O	130	137	locally
O	138	147	recurrent
O	148	150	or
O	151	161	metastatic
O	162	170	estrogen
O	171	179	receptor
O	179	180	-
O	180	188	positive
O	189	195	breast
O	196	202	cancer
O	203	214	progressing
O	215	217	on
O	218	227	treatment
O	228	232	with
O	233	234	a
O	235	247	nonsteroidal
O	248	257	aromatase
O	258	267	inhibitor
O	267	268	.

O	269	279	Entinostat
O	280	282	is
O	283	285	an
O	286	290	oral
O	291	298	isoform
O	299	308	selective
O	309	316	histone
O	317	328	deacetylase
O	329	338	inhibitor
O	339	343	that
O	344	351	targets
O	352	362	resistance
O	363	365	to
O	366	374	hormonal
O	375	384	therapies
O	385	387	in
O	388	396	estrogen
O	397	405	receptor
O	405	406	-
O	406	414	positive
O	415	416	(
O	416	418	ER
O	418	419	+
O	419	420	)
O	421	427	breast
O	428	434	cancer
O	434	435	.

O	436	440	This
O	441	451	randomized
O	451	452	,
O	453	460	placebo
O	460	461	-
O	461	471	controlled
O	471	472	,
O	473	478	phase
O	479	481	II
O	482	487	study
O	488	497	evaluated
O	498	508	entinostat
O	509	517	combined
O	518	522	with
O	523	526	the
O	527	536	aromatase
O	537	546	inhibitor
O	547	557	exemestane
O	558	564	versus
O	565	575	exemestane
O	576	581	alone
O	581	582	.

B-eligibility	583	597	Postmenopausal
I-eligibility	598	603	women
I-eligibility	604	608	with
I-eligibility	609	611	ER
I-eligibility	611	612	+
I-eligibility	613	621	advanced
I-eligibility	622	628	breast
I-eligibility	629	635	cancer
I-eligibility	636	647	progressing
I-eligibility	648	650	on
I-eligibility	651	652	a
I-eligibility	653	665	nonsteroidal
I-eligibility	666	675	aromatase
I-eligibility	676	685	inhibitor
O	686	690	were
O	691	699	randomly
O	700	708	assigned
O	709	711	to
O	712	722	exemestane
O	723	725	25
O	726	728	mg
O	729	734	daily
O	735	739	plus
O	740	750	entinostat
O	751	752	5
O	753	755	mg
O	756	760	once
O	761	764	per
O	765	769	week
O	770	771	(
O	771	773	EE
O	773	774	)
O	775	777	or
B-control	778	788	exemestane
I-control	789	793	plus
I-control	794	801	placebo
I-control	802	803	(
I-control	803	805	EP
I-control	805	806	)
O	806	807	.

O	808	811	The
O	812	819	primary
O	820	823	end
O	824	829	point
O	830	833	was
B-outcome-Measure	834	845	progression
I-outcome-Measure	845	846	-
I-outcome-Measure	846	850	free
I-outcome-Measure	851	859	survival
I-outcome-Measure	860	861	(
I-outcome-Measure	861	864	PFS
I-outcome-Measure	864	865	)
O	865	866	.

O	867	872	Blood
O	873	876	was
O	877	886	collected
O	887	889	in
O	890	891	a
O	892	898	subset
O	899	901	of
O	902	910	patients
O	911	914	for
O	915	925	evaluation
O	926	928	of
O	929	936	protein
O	937	943	lysine
O	944	955	acetylation
O	956	958	as
O	959	960	a
O	961	970	biomarker
O	971	973	of
O	974	984	entinostat
O	985	993	activity
O	993	994	.

B-total-participants	995	998	One
I-total-participants	999	1006	hundred
I-total-participants	1007	1013	thirty
O	1014	1022	patients
O	1023	1027	were
O	1028	1036	randomly
O	1037	1045	assigned
O	1046	1047	(
O	1047	1049	EE
O	1050	1055	group
O	1055	1056	,
O	1057	1058	n
O	1059	1060	=
B-intervention-participants	1061	1063	64
O	1063	1064	;
O	1065	1067	EP
O	1068	1073	group
O	1073	1074	,
O	1075	1076	n
O	1077	1078	=
B-control-participants	1079	1081	66
O	1081	1082	)
O	1082	1083	.

O	1084	1089	Based
O	1090	1092	on
O	1093	1099	intent
O	1099	1100	-
O	1100	1102	to
O	1102	1103	-
O	1103	1108	treat
O	1109	1117	analysis
O	1117	1118	,
O	1119	1128	treatment
O	1129	1133	with
O	1134	1136	EE
O	1137	1145	improved
B-outcome	1146	1152	median
I-outcome	1153	1156	PFS
O	1157	1159	to
B-iv-cont-median	1160	1161	4
I-iv-cont-median	1161	1162	.
I-iv-cont-median	1162	1163	3
I-iv-cont-median	1164	1170	months
O	1171	1177	versus
B-cv-cont-median	1178	1179	2
I-cv-cont-median	1179	1180	.
I-cv-cont-median	1180	1181	3
I-cv-cont-median	1182	1188	months
O	1189	1193	with
O	1194	1196	EP
O	1197	1198	(
O	1198	1204	hazard
O	1205	1210	ratio
O	1211	1212	[
O	1212	1214	HR
O	1214	1215	]
O	1215	1216	,
O	1217	1218	0
O	1218	1219	.
O	1219	1221	73
O	1221	1222	;
O	1223	1225	95
O	1225	1226	%
O	1227	1229	CI
O	1229	1230	,
O	1231	1232	0
O	1232	1233	.
O	1233	1235	50
O	1236	1238	to
O	1239	1240	1
O	1240	1241	.
O	1241	1243	07
O	1243	1244	;
O	1245	1248	one
O	1248	1249	-
O	1249	1254	sided
O	1255	1256	P
O	1257	1258	=
O	1259	1260	.
O	1260	1263	055
O	1263	1264	;
O	1265	1268	two
O	1268	1269	-
O	1269	1274	sided
O	1275	1276	P
O	1277	1278	=
O	1279	1280	.
O	1280	1282	11
O	1283	1284	[
O	1284	1294	predefined
O	1295	1307	significance
O	1308	1313	level
O	1314	1316	of
O	1317	1318	.
O	1318	1320	10
O	1320	1321	,
O	1322	1325	one
O	1325	1326	-
O	1326	1331	sided
O	1331	1332	]
O	1332	1333	)
O	1333	1334	.

B-outcome	1335	1341	Median
I-outcome	1342	1349	overall
I-outcome	1350	1358	survival
O	1359	1362	was
O	1363	1365	an
O	1366	1377	exploratory
O	1378	1381	end
O	1382	1387	point
O	1388	1391	and
O	1392	1400	improved
O	1401	1403	to
B-iv-cont-median	1404	1406	28
I-iv-cont-median	1406	1407	.
I-iv-cont-median	1407	1408	1
I-iv-cont-median	1409	1415	months
O	1416	1420	with
O	1421	1423	EE
O	1424	1430	versus
B-cv-cont-median	1431	1433	19
I-cv-cont-median	1433	1434	.
I-cv-cont-median	1434	1435	8
I-cv-cont-median	1436	1442	months
O	1443	1447	with
O	1448	1450	EP
O	1451	1452	(
O	1452	1454	HR
O	1454	1455	,
O	1456	1457	0
O	1457	1458	.
O	1458	1460	59
O	1460	1461	;
O	1462	1464	95
O	1464	1465	%
O	1466	1468	CI
O	1468	1469	,
O	1470	1471	0
O	1471	1472	.
O	1472	1474	36
O	1475	1477	to
O	1478	1479	0
O	1479	1480	.
O	1480	1482	97
O	1482	1483	;
O	1484	1485	P
O	1486	1487	=
O	1488	1489	.
O	1489	1492	036
O	1492	1493	)
O	1493	1494	.

B-outcome	1495	1502	Fatigue
I-outcome	1503	1506	and
I-outcome	1507	1518	neutropenia
O	1519	1523	were
O	1524	1527	the
O	1528	1532	most
O	1533	1541	frequent
B-outcome	1542	1547	grade
I-outcome	1548	1549	3
I-outcome	1549	1550	/
I-outcome	1550	1551	4
I-outcome	1552	1562	toxicities
O	1562	1563	.

B-outcome	1564	1573	Treatment
I-outcome	1574	1589	discontinuation
O	1590	1597	because
O	1598	1600	of
B-outcome	1601	1608	adverse
I-outcome	1609	1615	events
O	1616	1619	was
O	1620	1626	higher
O	1627	1629	in
O	1630	1633	the
O	1634	1636	EE
O	1637	1642	group
O	1643	1649	versus
O	1650	1653	the
O	1654	1656	EP
O	1657	1662	group
O	1663	1664	(
B-iv-bin-percent	1664	1666	11
I-iv-bin-percent	1666	1667	%
O	1668	1669	v
B-cv-bin-percent	1670	1671	2
I-cv-bin-percent	1671	1672	%
O	1672	1673	)
O	1673	1674	.

O	1675	1682	Protein
O	1683	1689	lysine
O	1690	1706	hyperacetylation
O	1707	1709	in
O	1710	1713	the
O	1714	1716	EE
O	1717	1726	biomarker
O	1727	1733	subset
O	1734	1737	was
O	1738	1748	associated
O	1749	1753	with
O	1754	1763	prolonged
O	1764	1767	PFS
O	1767	1768	.

O	1769	1779	Entinostat
O	1780	1785	added
O	1786	1788	to
O	1789	1799	exemestane
O	1800	1802	is
O	1803	1812	generally
O	1813	1817	well
O	1818	1827	tolerated
O	1828	1831	and
O	1832	1844	demonstrated
O	1845	1853	activity
O	1854	1856	in
O	1857	1865	patients
O	1866	1870	with
O	1871	1873	ER
O	1873	1874	+
O	1875	1883	advanced
O	1884	1890	breast
O	1891	1897	cancer
O	1898	1900	in
O	1901	1905	this
O	1906	1912	signal
O	1912	1913	-
O	1913	1920	finding
O	1921	1926	phase
O	1927	1929	II
O	1930	1935	study
O	1935	1936	.

O	1937	1948	Acetylation
O	1949	1956	changes
O	1957	1960	may
O	1961	1968	provide
O	1969	1971	an
O	1972	1983	opportunity
O	1984	1986	to
O	1987	1995	maximize
O	1996	2004	clinical
O	2005	2012	benefit
O	2013	2017	with
O	2018	2028	entinostat
O	2028	2029	.

O	2030	2035	Plans
O	2036	2039	for
O	2040	2041	a
O	2042	2054	confirmatory
O	2055	2060	study
O	2061	2064	are
O	2065	2073	underway
O	2073	2074	.
